Skip to main content
Evidence Snapshot

Muscle, skeletal receptor tyrosine-protein kinase

CHEMBL5684 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5684
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Muscle, skeletal receptor tyrosine-protein kinase as ChEMBL target CHEMBL5684, mapped to UniProt O15146. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Muscle, skeletal receptor tyrosine-protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5684
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O15146
Muscle, skeletal receptor tyrosine-protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Muscle, skeletal receptor tyrosine-protein kinase matters

As of 2026-09-14

Muscle, skeletal receptor tyrosine-protein kinase is reviewed as Muscle, skeletal receptor tyrosine-protein kinase (UniProt O15146); the current evidence base includes 7 approved drugs, 963 compounds, and 241 assays, with lead potency reaching pChEMBL 8.5.

Protein context
Muscle, skeletal receptor tyrosine-protein kinase

Muscle, skeletal receptor tyrosine-protein kinase Sequence length is 869 aa.

Review this target as Muscle, skeletal receptor tyrosine-protein kinase, mapped to UniProt O15146. Sequence length is 869 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt O15146 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 963 compounds, and 241 assays for this target. The dominant activity type is KD. CHEMBL574738 is the current potency anchor at pChEMBL 8.5.

Use CHEMBL574738 as the tractability anchor when discussing potency (pChEMBL 8.5).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 8.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Muscle, skeletal receptor tyrosine-protein kinase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O15146, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

963
Total Compounds
241
Total Assays
7
Approved Drugs
IC50: 26.0, KI: 1.0, KD: 123.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL574738
 8.5 Kd —
No preferred name
CHEMBL388978
 8.4 IC50 —
No preferred name
CHEMBL601719
 8.0 IC50 Approved
No preferred name
CHEMBL223360
 8.0 Kd Clinical
No preferred name
CHEMBL1230609
 7.9 Kd Clinical

Approved Drugs

Structure Compound First Approval
QUIZARTINIB
CHEMBL576982
 2023
FEDRATINIB
CHEMBL1287853
 2019
NINTEDANIB
CHEMBL502835
 2014
CRIZOTINIB
CHEMBL601719
 2011
SUNITINIB
CHEMBL535
 2006
SORAFENIB
CHEMBL1336
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5684